Drug-Induced Hair Loss
Hair loss is a recognized side effect of dozens of common medications. Some have it explicitly on their labels; others are well-documented in the medical literature without being prominently labeled; others are debated. The most common mechanism is telogen effluvium, a diffuse synchronized shedding that develops two to three months after starting the medication. A separate and more dramatic mechanism, anagen effluvium, is responsible for chemotherapy-related hair loss. A third pattern, drug-induced pattern hair loss, occurs when a medication shifts the androgen environment in genetically susceptible people (testosterone replacement is the clearest example).
This pillar covers the framework for recognizing drug-induced hair loss across categories, the timing and pattern that distinguishes it from other causes, and what to do if you suspect a medication you take is contributing. Child pages cover the highest-volume specific drugs in more depth.
The three mechanisms
Telogen effluvium, the most common drug-induced mechanism, pushes a cohort of follicles into the resting phase of the hair cycle. They shed three to four months later, producing a diffuse shedding pattern that resolves once the trigger resolves. The lag time between the medication and the visible shedding is the most characteristic feature.
Anagen effluvium, the mechanism behind chemotherapy-related hair loss, damages actively growing hair shafts directly. Shedding is rapid (within weeks of starting treatment) and often dramatic. It recovers fully after treatment ends in most cases, sometimes with temporary changes in color or texture.
Drug-induced pattern hair loss occurs when a medication shifts the androgen environment in genetically susceptible patients. Testosterone replacement therapy in men with susceptible follicles is the classic example: the increased testosterone provides more substrate for local conversion to DHT, accelerating pattern loss at the temples and crown. Some forms of birth control with high-androgenicity progestins can do the same in women.
Distinguishing which mechanism is at play matters because the response differs. Telogen effluvium resolves on its own once the trigger is removed; anagen effluvium recovers when the chemotherapy ends; drug-induced pattern loss continues until either the medication is changed or the underlying pattern loss is treated directly.
Categories of medications associated with hair loss
The categories below are not exhaustive. They represent the medications with the strongest associations and the highest patient-relevance.
GLP-1 weight-loss medications
Semaglutide and tirzepatide (and the older GLP-1 agonists like liraglutide) have hair loss reports that have grown substantially with the explosive rise in their use for weight management. The labeling for both medications now includes alopecia as a possible adverse effect. The underlying mechanism appears to be the rapid weight loss they produce rather than the drug itself: any rapid weight loss is a well-established trigger for telogen effluvium, and the shedding pattern matches the typical telogen course. The GLP-1 page covers this in depth.
Metformin
Metformin's hair-loss signal is mediated through vitamin B12 deficiency. Long-term metformin use reduces B12 absorption, and B12 deficiency can drive diffuse shedding. The fix is usually B12 supplementation rather than stopping metformin, since diabetes management generally takes precedence and the deficiency is correctable. Our metformin page covers the B12 mechanism and the practical monitoring.
Antidepressants
SSRIs (sertraline, fluoxetine, escitalopram, paroxetine), SNRIs (venlafaxine, duloxetine), bupropion, and tricyclics have all been associated with telogen effluvium in some users. The strength of the signal varies by drug and across patients. Bupropion has one of the more consistent associations.
Birth control and hormonal contraceptives
The effect on hair varies by formulation. Pills with high-androgenicity progestins (older norethindrone-based pills, some levonorgestrel formulations) can drive pattern hair loss in susceptible women. Pills with anti-androgenic progestins (drospirenone, dienogest) or those that increase sex hormone-binding globulin are usually neutral or mildly protective. Starting or stopping any hormonal contraceptive can trigger a telogen effluvium through the hormonal shift.
Blood thinners
Warfarin has the strongest signal of the anticoagulants. Heparin in long-term use has occasional reports. Direct oral anticoagulants (DOACs) like apixaban and rivaroxaban have less consistent data, but reports exist.
Cardiovascular medications
Beta blockers (propranolol, metoprolol, atenolol), ACE inhibitors (lisinopril, enalapril), and some calcium channel blockers have hair loss listed in their labeling. Absolute incidence is low, and patients on these medications for life-altering conditions usually continue them and address the hair effect separately if it occurs.
Statins
Atorvastatin, simvastatin, and other statins have occasional published reports of telogen effluvium. The signal is weaker than for the categories above, and most patients on statins do not experience meaningful hair effects.
Anticonvulsants
Valproate has the strongest signal in this category (used for seizures and bipolar disorder; hair loss can be substantial). Gabapentin has a smaller but real signal. Lamotrigine and topiramate have occasional reports.
Retinoids
Oral isotretinoin (for severe acne) and high-dose vitamin A supplements can cause telogen effluvium that persists while the medication is being taken. The shedding usually resolves after discontinuation.
Hormonal cancer therapies
Tamoxifen and aromatase inhibitors (anastrozole, letrozole, exemestane), used for breast cancer treatment and prevention, have well-documented hair shedding that often persists for the duration of treatment (typically 5 to 10 years). The mechanism is the reduction in estrogen activity at the follicle.
Chemotherapy
The mechanism here is distinct (anagen effluvium rather than telogen effluvium). Cytotoxic chemotherapy drugs (taxanes, anthracyclines, alkylating agents) damage the actively dividing cells of growing hair shafts. Shedding starts within two to three weeks and can be near-total. Recovery usually begins within months of treatment ending, though some agents (particularly taxanes) have associations with permanent hair loss in a minority of patients.
Radiation
Radiation to the scalp causes localized hair loss in the treated field. Low doses produce temporary shedding; high doses can produce permanent loss in the area treated.
How to recognize drug-induced hair loss
The framework for distinguishing drug-induced hair loss from other causes has four key questions:
Timing. Did the shedding start two to three months after a new medication, a dose change, or a change in regimen? Drug-induced telogen effluvium has a characteristic delay.
Pattern. Is the shedding diffuse across the whole scalp, or focal at the temples and crown? Drug-induced hair loss is almost always diffuse, with exceptions like testosterone replacement-related pattern acceleration.
Other triggers. Did anything else change around the same time? Illness, surgery, rapid weight loss, major life stressor, pregnancy and delivery can all trigger telogen effluvium independently and complicate the analysis.
Underlying conditions. Is there a coexisting condition that can cause shedding (thyroid disease, iron deficiency, B12 deficiency, PCOS) that the medication might be masking or interacting with? A focused panel of labs is usually worth doing.
What to do
The single most important caveat: do not stop a medication on your own to test whether it is causing hair loss. Many of the medications associated with hair shedding are taken for important reasons (cardiovascular protection, mood stabilization, cancer treatment), and abrupt discontinuation can have serious consequences. Trial discontinuation is sometimes the right move, but it is a decision made with the prescribing physician, often with a substitute drug ready.
The general approach when drug-induced hair loss is suspected:
- Identify the temporal relationship between starting the medication and the onset of shedding. Note when each began.
- Rule out other contributors with a focused panel of labs.
- Address any modifiable contributors (B12 deficiency in metformin users, low ferritin in any patient).
- Discuss with the prescribing physician whether the medication is essential and whether alternatives exist.
- If the medication must continue, consider treating any coexisting pattern hair loss directly, since drug-induced shedding can unmask underlying pattern loss.
When the medication is essential
For medications that cannot be safely discontinued (chemotherapy, hormonal cancer therapy, blood thinners after a clot, antiseizure medications), the conversation shifts to managing the hair effect rather than removing the cause.
Practical options include:
- Treating any coexisting androgenetic alopecia directly with topical or oral minoxidil under physician supervision, when not contraindicated
- Addressing modifiable contributors (deficiencies, sleep, nutrition) that may be amplifying the shedding
- In some cases, scalp cooling during chemotherapy infusions to reduce anagen effluvium severity
- Patience with the recovery timeline once treatment ends
The hair loss in women cluster covers post-cancer hair recovery in more depth where the medications are tamoxifen and aromatase inhibitors.
When to consult
If shedding has clearly started within months of a new medication and the pattern is diffuse, a conversation with the prescribing physician is the right next step. A telehealth or in-person assessment can confirm whether what you are seeing fits a telogen effluvium pattern, identify any other contributors with appropriate labs, and frame the trade-off between continuing the medication and changing it. Curekey's hair assessment is one way to start with a U.S.-licensed physician. The companion guide on medications and hair loss covers the diagnostic framework in more depth.
